Bristol Myers teams with Microsoft to deploy AI for early lung cancer detection across US hospitals

Bristol Myers partners with Microsoft for AI-driven lung cancer detection

Bristol Myers Squibb is joining forces with Microsoft. They will use artificial intelligence to find lung cancer earlier. This technology analyses X-ray and CT scans. The goal is to help doctors spot difficult nodules. It also aims to identify patients at earlier disease stages. Bristol Myers Squibb said on Tuesday it had signed an agreement with Microsoft to use the tech ⁠company's AI-enabled radiology platform to help speed up early detection of lung cancer. The collaboration will deploy US Food and Drug Administration-cleared radiology AI algorithms through Microsoft's Precision Imaging Network, which analyzes X-ray and CT images to help identify lung disease and is used by hospitals in the United States, the companies said. Bristol Myers said the tools could help clinicians spot hard-to-detect lung nodules and identify some patients at earlier stages of disease. The drugmaker said a key aim of the partnership is to expand access to early detection in medically underserved communities, including rural hospitals and community clinics across the United States. "By combining Microsoft's highly scalable radiology solutions with Bristol's deep expertise in oncology and drug delivery, we have envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with non-small cell lung cancer and guide them to optimal care pathways and precision therapies," said ⁠Alexandra Goncalves, ⁠Vice President and Head of Digital Health, Bristol Myers Squibb. Pharmaceutical companies have increasingly turned to artificial intelligence to accelerate R&D, betting that new modeling tools and automated labs can improve efficiency across their pipelines. Last week, AstraZeneca said it agreed to buy Boston-based Modella AI to speed oncology drug research.

Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With AI - Bristol-Myers Squibb (NYSE:BMY), Microsoft (NASDAQ:MSFT)

U.S. drug giant Bristol Myers Squibb Co (NYSE:BMY) has partnered with Microsoft Inc (NASDAQ:MSFT), aiming to accelerate early detection of lung cancer. The goal is to deploy U.S. FDA-cleared radiology AI algorithms through Microsoft's Precision Imaging Network. The platform, used by more than 80% of U.S. hospitals, applies AI to automatically analyze X-ray and CT scans, helping radiologists identify hard-to-detect lung nodules, flag patients earlier in the disease cycle and reduce clinical workload. The collaboration aims to expand access to early detection in medically underserved communities, including rural hospitals and community clinics. Lung cancer remains the leading cause of cancer deaths in the U.S., with about 125,000 deaths and 227,000 new cases each year. Underserved populations face higher mortality rates and lower screening rates, and more than half of patients with incidental findings are lost to follow-up -- an issue the partnership seeks to address through workflow tools that track patients and support ongoing care. "By combining Microsoft's highly scalable radiology solutions with BMS' deep expertise in oncology and drug delivery, we've envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies," said Alexandra Goncalves, VP and Head of Digital Health, Bristol Myers Squibb. Last week, OpenAI acquired the health care technology startup Torch, days after the company unveiled ChatGPT Health, a platform designed to help patients and doctors navigate complex medical information. Price Action: BMY stock is down 0.81% at $54.81, and MSFT stock is down 1.24% at $454.07 at the last check on Tuesday. Image: Shutterstock BMYBristol-Myers Squibb Co $54.53-1.31% Overview MSFTMicrosoft Corp $453.31-1.43% Market News and Data brought to you by Benzinga APIs